Torray Investment Partners LLC Invests $3.37 Million in Pfizer Inc. (NYSE:PFE)

Key Points

• Torray Investment Partners LLC acquired 133,144 shares of Pfizer Inc. valued at approximately $3.37 million during the first quarter.
• Pfizer's most recent quarterly earnings report showed an EPS of $0.92, exceeding estimates, but its revenue fell short of expectations at $13.72 billion.
• The company has a current dividend yield of 7.22%, with an annualized dividend of $1.72, despite a payout ratio exceeding 124%.

Torray Investment Partners LLC purchased a new position in Pfizer Inc. (NYSE:PFE - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 133,144 shares of the biopharmaceutical company's stock, valued at approximately $3,374,000.

A number of other institutional investors have also bought and sold shares of the business. William B. Walkup & Associates Inc. boosted its holdings in shares of Pfizer by 1.2% during the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock valued at $1,044,000 after purchasing an additional 454 shares during the last quarter. Members Trust Co boosted its holdings in shares of Pfizer by 2.1% during the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock valued at $587,000 after purchasing an additional 467 shares during the last quarter. Sutton Place Investors LLC boosted its holdings in shares of Pfizer by 5.6% during the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock valued at $224,000 after purchasing an additional 472 shares during the last quarter. Bellevue Group AG lifted its holdings in shares of Pfizer by 0.3% in the 4th quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company's stock valued at $3,756,000 after acquiring an additional 485 shares during the last quarter. Finally, Gould Capital LLC lifted its holdings in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

PFE has been the subject of a number of analyst reports. Citigroup increased their price target on shares of Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Wolfe Research increased their price target on shares of Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a report on Wednesday, April 30th. BMO Capital Markets lowered their price target on shares of Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. Berenberg Bank lowered their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Finally, Morgan Stanley increased their price target on shares of Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $28.28.

Pfizer Stock Up 0.9%

PFE traded up $0.20 during trading on Friday, hitting $23.49. The stock had a trading volume of 51,287,529 shares, compared to its average volume of 38,018,180. The company has a market capitalization of $133.55 billion, a PE ratio of 17.02, a PEG ratio of 0.84 and a beta of 0.52. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.32. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The stock has a 50 day simple moving average of $24.36 and a two-hundred day simple moving average of $24.60.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. Pfizer's revenue was down 7.8% compared to the same quarter last year. During the same period last year, the firm earned $0.82 earnings per share. On average, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.3%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.